Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
Igarashi K, Kawaguchi K, Li S, Han Q, Tan Y, Murakami T, Kiyuna T, Miyake K, Miyake M, Singh AS, Eckardt MA, Nelson SD, Russell TA, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Singh SR, Eilber FC, Hoffman RM.
Igarashi K, et al. Among authors: miyake k, miyake m.
Cancer Lett. 2018 Mar 28;417:168-173. doi: 10.1016/j.canlet.2017.12.028. Epub 2018 Jan 3.
Cancer Lett. 2018.
PMID: 29306021